topo

Ser ju ungegär ut som obducats chart på 90 talet:-)

Aktiehandel går till stor del ut på att hitta undervärderade aktier som förbisetts av så många som möjligt, varför ska man då handla ngt som det skrivs spaltmeter om i chattarna,
o danskt är det  till på köpet.

...ögnade redeye analys "Topotarget är nordens utan konkurrens lägst värderade bioteknikbolag" undrar varför, det är inte förbisett i allafall.

Kan inget om bolaget, men jag skulle varit mkt försiktig.

Ny Vd utsedd Francois Martelet

Dr. Francois Martelet has a solid late-stage development and commercialisation
experience from the international pharmaceutical industry, including Merck &
Co., Novartis, Schering-Plough, Eli Lilly and Roche. During his time with Merck
& Co. (2005-2007), he was Vice President & Worldwide Franchise Head, Oncology,
from which position he has gained in-depth knowledge of the HDACi drug class
via his role in the global launch of Zolinza®. More recently (2007-2009), he
was President & CEO of , AVAX Technologies, Inc., a US biotech company which is
specialised in cancer vaccines therapy. Francois Martelet is a bilingual
English/French speaker, and commands both German and Swedish. He holds a
doctorate with distinction in medicine and a masters degree in business (from
the Dijon University of Medicine, Dijon, France), and a degree in legal
medicine (Descartes University of Medicine, Paris, France). In addition, he has
attended advanced management development programs at both Harvard Business
School and INSEAD. Francois Martelet is a French national and 50 years old.

The change of responsibilities will take place with immediate effect. In order
to ensure a successful transition, Professor Peter Buhl Jensen will, on a
fulltime consultative basis, be available for TopoTarget for a six months
period in order to facilitate a satisfactory transfer of knowledge. 

Nya vd kommentar

"I am extremely pleased to join TopoTarget. The Company has with its potential
best-in-class drug candidate, belinostat, an excellent platform for making a
difference in cancer treatment. On top of my agenda is to prepare the
commercialisation of belinostat together with Spectrum Pharmaceuticals in North
America, and in Europe, in Japan and in the emerging markets," said Dr.
Francois Martelet, new CEO of TopoTarget. "I look forward, together with the
dedicated team of TopoTarget, to maximising the value of this important asset
and to transform the Company into a leading European biotech company within
oncology." 


 

Mvh 528 Jamenvisst